Vera Therapeutics, Inc.2024财年第二财季实现净利润-33.71百万美元，同比减少67.21%

自选股智能写手08-17

8月17日，Vera Therapeutics, Inc.（VERA.US）公布财报，公告显示公司2024财年第二财季净利润为-33.71百万美元，同比减少67.21%；其中营业收入为0.00美元，每股基本收益为-0.62美元。从资产负债表来看，Vera Therapeutics, Inc.（VERA.US）总负债69.42百万美元，其中短期债务2.12百万美元，资产负债比为0.06，流动比率为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460418562?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-17 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460418562","market":"us","top_or_hot":-1,"title":"Vera Therapeutics, Inc.2024财年第二财季实现净利润-33.71百万美元，同比减少67.21%","media":"自选股智能写手","content":"<div>\n<p>8月17日，Vera Therapeutics, Inc.（VERA.US）公布财报，公告显示公司2024财年第二财季净利润为-33.71百万美元，同比减少67.21%；其中营业收入为0.00美元，每股基本收益为-0.62美元。从资产负债表来看，Vera Therapeutics, Inc.（VERA.US）总负债69.42百万美元，其中短期债务2.12百万美元，资产负债比为0.06，流动比率为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170006349f31b1c0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vera Therapeutics, Inc.2024财年第二财季实现净利润-33.71百万美元，同比减少67.21%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVera Therapeutics, Inc.2024财年第二财季实现净利润-33.71百万美元，同比减少67.21%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-17 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170006349f31b1c0&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月17日，Vera Therapeutics, Inc.（VERA.US）公布财报，公告显示公司2024财年第二财季净利润为-33.71百万美元，同比减少67.21%；其中营业收入为0.00美元，每股基本收益为-0.62美元。从资产负债表来看，Vera Therapeutics, Inc.（VERA.US）总负债69.42百万美元，其中短期债务2.12百万美元，资产负债比为0.06，流动比率为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170006349f31b1c0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VERA","symbol_name":"Vera Therapeutics, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170006349f31b1c0&s=b","article_id":"2460418562","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170006349f31b1c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460418562","pubTimestamp":1723824039,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月17日，Vera Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-33.71百万美元，同比减少67.21%；其中营业收入为0.00美元，每股基本收益为-0.62美元。从资产负债表来看，Vera Therapeutics, Inc.总负债69.42百万美元，其中短期债务2.12百万美元，资产负债比为0.06，流动比率为0.22。机构评级：截至2024年8月17日，当前有9家机构对Vera Therapeutics, Inc.目标价做出预测，其中目标均价为60.22美元，其中最低目标价为30.00美元，最高目标价为107.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"VERA":"Vera Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"Vera Therapeutics, Inc. achieved net profit of-US $33.71 million in the second fiscal quarter of fiscal 2024, a year-on-year decrease of 67.21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"VERA":1},"content_text":"8月17日，Vera Therapeutics, Inc.（VERA.US）公布财报，公告显示公司2024财年第二财季净利润为-33.71百万美元，同比减少67.21%；其中营业收入为0.00美元，每股基本收益为-0.62美元。从资产负债表来看，Vera Therapeutics, Inc.（VERA.US）总负债69.42百万美元，其中短期债务2.12百万美元，资产负债比为0.06，流动比率为0.22。机构评级：截至2024年8月17日，当前有9家机构对Vera Therapeutics, Inc.目标价做出预测，其中目标均价为60.22美元，其中最低目标价为30.00美元，最高目标价为107.00美元。公司简介：Vera Therapeutics Inc 是一家临床阶段的生物技术公司。 该公司专注于为患有严重免疫疾病的患者开发变革性疗法并将其商业化。 该公司的候选产品是 atacicept，是一种融合蛋白，每周皮下注射一次，可阻断 B 淋巴细胞刺激剂和增殖诱导配体，它们会刺激 B 细胞和浆细胞产生导致某些自身免疫性疾病的自身抗体。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460418562"}